APR 28, 2020 8:37 AM PDT

Is a multi-cancer detection blood test safe for women?

Earlier detection is essential in order to reduce deaths caused by cancer. A new study, DETECT-A (Detecting cancers Earlier Through Elective mutation-based blood Collection and Testing), has been published recently in the journal Science. Researchers conducting the study have developed a blood test called CancerSEEK that is capable of detecting eight common types of cancer with non-invasive methods. While the new blood test is not meant to replace other methods of early detection,  it is hoped that it will aid in improving detection among particular cancers that are difficult to detect, like ovarian cancer. 

The researchers caution that the study was not conducted with regulatory approval of a specific test in mind. Furthermore, they comment that larger formal trials will be imperative to determine the clinical validity and utility of CancerSEEK as a detection method. 

The study included women with no history of cancer, ages 65 to 75. Lead researcher, Anne Marie Lennon and her colleagues analyzed circulating DNA and protein biomarkers of cancer in the blood of the participating women. The researchers applied the CancerSEEK test to 1005 patients with nonmetastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast and found that the tests were positive in a median of 70% of the eight cancer types.

They found that some cancers were detected by blood analysis, while others were detected by other traditional detection means, like a full-body diagnostic positron emission tomography-computed tomography (PET-CT) scan. Over the 12-month study, 96 cancers were diagnosed in total. Twenty-six of these were detected by the blood test, 24 by standard screening, and 46 by other means. They write in their study: 

“The sensitivities ranged from 69 to 98% for the detection of five cancer types (ovary, liver, stomach, pancreas, and esophagus) for which there are no screening tests available for average-risk individuals. The specificity of CancerSEEK was greater than 99%: only 7 of 812 healthy controls scored positive. In addition, CancerSEEK localized the cancer to a small number of anatomic sites in a median of 83% of the patients.”

Photo: Pixabay

Another important follow-up conclusion from the study shows that women who underwent blood test detection did not significantly change their habits in regards to receiving other forms of detection screening. According to Eureka Alert, the fact that the women in the study did not have fewer mammograms after the baseline blood test than they had in the years prior suggests that such a test “can be incorporated into routine clinical care and not discourage participants from engaging in standard-of-care screening, which the authors emphasize their approach shouldn't replace.” 

Sources: Science, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUN 07, 2021
Cell & Molecular Biology
Overcoming Challenges to Detect Apoptosis in 3D Cell Structures
JUN 07, 2021
Overcoming Challenges to Detect Apoptosis in 3D Cell Structures
Researchers are increasingly relying on cells grown in three-dimensional (3D) structures to help answer their research q ...
JUN 27, 2021
Cancer
Are e-cigarettes actually helpful for smoking cessation?
JUN 27, 2021
Are e-cigarettes actually helpful for smoking cessation?
New research published in The Lancet Public Health reports on a study that looked at interventions targeting e-cigarette ...
JUL 07, 2021
Cancer
Chemotherapy Disrupts Gut Bacteria in Cancer Patients
JUL 07, 2021
Chemotherapy Disrupts Gut Bacteria in Cancer Patients
Researchers from Australia have found that the conventional chemotherapy used to treat various cancers disrupts the comp ...
JUL 26, 2021
Genetics & Genomics
A Region of Non-Coding DNA That May Help Regulate Telomere Length is ID'ed
JUL 26, 2021
A Region of Non-Coding DNA That May Help Regulate Telomere Length is ID'ed
Many types of cells have to be replenished continuously throughout our lives, and the genome in the nucleus of those cel ...
AUG 04, 2021
Health & Medicine
Cannabis Drug Sativex to Be Tested in Phase II Brain Tumor Trial
AUG 04, 2021
Cannabis Drug Sativex to Be Tested in Phase II Brain Tumor Trial
  A phase II trial is being planned to test the cannabis-derived drug Sativex, in patients with aggressive brain tu ...
AUG 24, 2021
Technology
CRISPR Helps Identify New Therapeutic Target for Leukemia
AUG 24, 2021
CRISPR Helps Identify New Therapeutic Target for Leukemia
Researchers may have found a new druggable target in patients with acute myeloid leukemia (AML), thanks to a CRISPR scre ...
Loading Comments...